CVM CVM
Company Profile ↓Company Overview
CVM (CVM) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +65.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -34.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -34.88% |
| 1 Year: | 65.45% |
Stock Price Performance
| 1 Year: | -83.57% |
| 6 Months: | -70.99% |
| 3 Months: | -12.64% |
| 1 Month: | +18.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)65.51 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -34.9% CAGR over 5 years.
- Trading 88.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113.14K | 67.16K | 15.91K | 67.82K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -5.93M | -6.23M | -6.90M | - | -10.00M | -7.76M | -8.20M | - | -5.78M | -6.27M | -6.38M | -4.94M | -7.91M | -4.76M | -4.93M | -4.22M | -4.09M | -5.03M | -4.31M | -5.21M | -6.86M | -6.72M | -6.97M | -8.73M | -8.53M | -10.46M | -8.84M | -9.55M | -8.72M | -7.65M | -8.18M | -8.18M | -6.49M | -7.08M | -6.67M | -6.89M | -6.39M | -5.49M | -5.37M | -5.33M |
| Net Income | -4.33M | -13.37M | -2.44M | -7.22M | -7.85M | -12.56M | -4.43M | - | 2.34M | -8.84M | -3.85M | 3.52M | -8.43M | -4.46M | -6.19M | -4.71M | -6.01M | 1.25M | -6.45M | -12.08M | -5.53M | -9.07M | -10.28M | -7.94M | -11.28M | -8.94M | -8.78M | -9.82M | -9.63M | -7.85M | -8.34M | -8.37M | -6.71M | -7.24M | -6.86M | -7.07M | -6.57M | -5.66M | -5.47M | -5.47M |
| Diluted EPS | -0.15 | -0.24 | -0.11 | -0.13 | -0.14 | -0.17 | -0.06 | -0.10 | 0.02 | - | -0.03 | 0.32 | -1.15 | -0.53 | -0.53 | -0.31 | -0.36 | 0.02 | -0.22 | - | -0.16 | -0.25 | -0.27 | -0.21 | -0.28 | -0.25 | -0.20 | -0.23 | -0.23 | -0.18 | - | - | -0.14 | -0.14 | -4.18 | -3.25 | -2.33 | -1.36 | -0.68 | -0.67 |
| R&D Expense | 4.02M | 4.15M | 4.45M | - | 4.85M | 5.08M | 5.73M | - | 5.17M | 4.63M | 4.84M | 3.55M | 6.58M | 3.18M | 2.33M | 2.96M | 2.43M | 3.47M | 2.83M | 2.30M | 4.25M | 4.46M | 3.97M | 5.41M | 5.22M | 7.18M | 6.08M | 6.52M | 6.29M | 5.39M | 6.08M | 5.73M | 4.35M | 4.63M | 4.70M | 4.43M | 4.01M | 3.74M | 3.68M | 3.77M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 956.15K | 254.61K | 159.58K | 264.03K | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -12.02M | -18.56M | -17.99M | -17.24M | -19.87M | -27.57M | -34.30M | -23.65M | -21.41M | -16.77M | -20.20M | -28.99M | -36.19M | -36.06M | -31.48M | -26.35M | -24.81M |
| Net Income | -40.91M | 10.48M | -25.71M | -15.48M | -9.17M | -27.37M | -34.67M | -11.51M | -14.36M | -31.84M | -22.13M | -30.26M | -36.36M | -36.70M | -32.37M | -26.92M | -25.41M |
| Diluted EPS | -0.31 | -0.06 | -1.49 | -0.78 | -0.66 | -0.49 | -0.42 | -2.37 | -1.91 | -1.87 | -0.71 | -0.82 | -0.90 | -0.87 | -0.73 | -15.31 | -6.27 |
| R&D Expense | 6.01M | 11.91M | 11.75M | 10.37M | 12.68M | 17.17M | 21.10M | 17.45M | 15.61M | 10.91M | 12.66M | 17.84M | 23.11M | 25.36M | 22.47M | 18.16M | 15.89M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2008 | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 37.80M | 18.63M | 16.07M | 10.84M | 19.23M | 15.45M | 24.89M | 22.92M | 29.59M | 27.62M | 40.54M | 75.87M | 50.52M | 30.53M | 26.99M | 28.16M |
| Total Equity | 10.84M | 8.84M | 27.85M | 9.08M | 7.03M | 6.70M | 10.44M | -4.76M | -679.21K | -3.34M | 916 | 5.13M | 19.73M | 56.53M | 32.16M | 13.21M | 12.87M | 15.96M |
| Cash & Equivalents | 711.26K | 33.57M | 26.57M | 4.26M | 3.94M | 41.61K | 8.51M | 5.73M | 2.92M | 2.37M | 10.31M | 8.44M | 15.51M | 36.06M | 22.67M | - | - | - |
| Total Liabilities | - | - | 9.95M | 9.55M | 9.04M | 4.14M | 8.79M | 20.53M | 25.57M | 26.26M | 29.59M | 22.49M | 20.81M | 19.34M | 18.36M | 17.31M | 14.12M | 12.20M |
| Current Liabilities | - | - | 3.30M | 7.22M | 1.91M | 3.55M | 3.15M | 6.71M | 4.01M | 10.84M | 9.23M | 3.02M | 4.27M | 3.94M | 4.66M | 5.59M | 4.62M | 5.13M |
Cash Flows (Annual)
Figures in USD.
| Metric | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -6.51M | -12.80M | -22.56M | -12.19M | -13.55M | -22.93M | -23.83M | -23.08M | -13.79M | -13.39M | -16.32M | -15.28M | -18.79M | -18.24M | -22.85M | -18.81M | -17.12M |
| Investing Cash Flow | 368.72K | -503.94K | -318.11K | -133.60K | -132.76K | -138.86K | -93.53K | -34.22K | -17.00K | -58.14K | -335.84K | -2.69M | -15.18M | 5.49M | -372.26K | -108.09K | -38.11K |
| Financing Cash Flow | 39.00M | 6.31M | 565.87K | 12.00M | 9.78M | 31.54M | 21.14M | 20.31M | 13.26M | 21.39M | 14.79M | 25.04M | 54.52M | -638.43K | 4.69M | 19.51M | 23.37M |
| Capital Expenditure | 191.87K | -493.74K | -216.76K | -54.64K | -102.03K | -103.98K | -73.40K | -31.41K | -10.53K | -1.01K | 177.78K | -2.65M | -9.02M | -637.89K | -361.89K | -94.88K | -38.11K |
| Free Cash Flow | -6.32M | -13.30M | -22.77M | -12.24M | -13.65M | -23.03M | -23.91M | -23.11M | -13.80M | -13.39M | -16.14M | -17.93M | -27.80M | -18.88M | -23.21M | -18.91M | -17.16M |
Ratios (Annual)
Figures in %.
| Metric | Sep 2009 | Sep 2010 | Sep 2011 | Sep 2012 | Sep 2013 | Sep 2014 | Sep 2015 | Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -1,881.0% | -6,772.3% | -12,450.1% | -10,443.4% | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | -2,689.1% | -6,078.8% | -5,746.8% | -10,364.7% | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | -462.7% | 37.6% | -283.2% | -220.2% | -136.9% | -262.0% | 728.1% | 1,695.0% | 430.4% | -3,475,677.4% | -431.2% | -153.4% | -64.3% | -114.1% | -244.9% | -209.2% | -159.2% |
| ROCE % | - | -53.8% | -157.8% | -121.8% | -272.4% | -171.5% | -392.3% | -113.3% | -177.2% | -82.4% | -82.1% | -79.9% | -50.3% | -78.6% | -126.2% | -117.8% | -107.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CVM
Before surgery, Multikine cut disease-progression risk 49% in study - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNOHE0ZF9HOV9scG56SDBPTXc0bnRQem9odEVwakVsZi01YmQ5OEY5MlNYTng0dGktbEJwMURSb1gyWGhyczB1ang2a1ZrdUh4M1JiWnJ0YWhjbnpFbVc2cHlGTUdkT1l3Z25aNWtqNzdCbTVKdTd4akFZSlJWQ0Jma1A4enc1MklnS3h4U0…
CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdm5ldXNSMEZRQ2NTQWVNd1lMVHpHaExiRV9jMlctVDJHZjBzbXhnUmlOSXF3aGFBRjBEQnl5NE5yVlItY05OYzNKQTlZY3BnU2dDSkVBeTlUTTdpXzY3czZNbVhkOGNidE9WZENkcnl3b3ZCMjFKSWJqWDF1b2pCUG9OSVE1UnZxRC0xaE…
$CVM stock is down 26% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOYUNDVFFLTkJ1RUZiVmFEWTdFaUo2Y3JaU1FKN1E0SXRLYVNsa2trU0pzYzdldUw3NElmVEMyb3VaR3BBZTVGRTh0dS0yLXQtZU4wcTZZdG9JQkdyRFNPZXh5cTQ0clpDMTNJX1dXV2lVN0RuTmlwS2xYWkc2ZGVYUnBfbDNvbWtWZlNCSk…
Cel-Sci Corporation (CVM) Stock Analysis: Exploring A Potential 823.91% Upside - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQNEZqbmxMSmEwZzZQN0hJekg2Q3MyNEhoS2dQZG1RZWROc3NvZGQzdURlUHdOX2U5Q1MzTnNXSG9lU09ZdE5yNC1wX1RUSVJrSkZKYUFKSkN5UVNTd0toQmJMdmZDTmE5R1NiMHVNUDczQTNZWDEyN1M0S1haaTBWeWUtLVBfOFBKVlN0TW…
CEL-SCI Corporation (CVM) Prices Public Offering, Shares Drop in Premarket - GuruFocus
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxQanRxTjNPc0otekxtNEtudUJ2TFFscTNUMEtXNVphcWFJN3Buc1k5UHVzdGtZS2FWaTRvWjlnNnhLaGM4cXcyYlE1aDhmV3ZxeGJla0JjY2tsT3duZWllcVUxY2xIREJrSC1WajJmM08wc2F1ZWJkdFF1aVhjcnZ3dVNwWkNYa2FoZThQeX…
CVM|CEL-SCI Corp|Price:1.160|Chg%:-0.055 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE80QXZFU1pFaS1LeW9Ob3dWLWphUkRGTXpTS2RaVnJwWnZvQU9WTE9KbTN0N0Q4YlJ5X09yaVhkQ3RoUGRfYkFLU3VrcEUyT3NoUzhWcnlpUFRmYWdFSVZBcFdtaWJXYkdlQ3lGNQ?oc=5" target="_blank">CVM|CEL-SCI Corp|Pric…
CVM — Frequently Asked Questions
What is the current share price of CVM?
As of 2026-08-05 17:25 PDT, CVM trades at $1.52 on NASDAQ/NYSE. Its 52-week range is $0.97 to $13.04.
What is the P/E ratio of CVM?
CVM trades at a trailing price-to-earnings (P/E) ratio of -0.24.
Is CVM a good stock to buy?
This page provides a data-driven analysis of CVM, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.